At present, among gynecological cancer, only in advanced cervical carcinomas there is an FDA-approved ICI in which PD-L1 immunostaining is enlisted for checkpoint inhibitor access based on PD-L1 CPS status ≥1 as stated in the phase 2 Keynote 158 [64] and phase 3 Keynote 826 trials [65]. This evidence concerns the gene CD274 and cervical carcinoma.